Title : Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.

Pub. Date : 2019 Nov 24

PMID : 31771279






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In support of these findings, a preliminary improved anti-cancer response was observed in a CRC PDX harboring mutated KRAS with intrinsically high AKT activity using GC1118 combined with the dual PI3K/mammalian target of rapamycin (mTOR)/AKT inhibitor BEZ-235, without observed toxicity. dactolisib KRAS proto-oncogene, GTPase Homo sapiens